Search Results

Data Presented at the AVA Annual Scientific Meeting Shows Significantly Lower Complication and Failure Rates with Access Vascular’s HydroMID® Midline Catheter

Access Vascular, Inc. announced findings from new data showing a reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters and midline catheters with AVI’s MIMIX® hydrophilic biomaterial compared with conventional catheters.

A growing body of clinical evidence supports the use of Firefly’s FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia

Access Vascular, Inc. announced that the Infusion Nurses Society has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.

Access Vascular, Inc. announced that it raised a Series C round worth $22 million from a consortium of new and existing investors.

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).